Hikari Power’s Alpine Immune Sciences Inc ALPN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-12,445
Closed -$493K 63
2024
Q1
$493K Hold
12,445
0.04% 55
2023
Q4
$237K Hold
12,445
0.02% 60
2023
Q3
$142K Hold
12,445
0.01% 61
2023
Q2
$128K Hold
12,445
0.01% 61
2023
Q1
$96K Hold
12,445
0.01% 63
2022
Q4
$91K Hold
12,445
0.01% 62
2022
Q3
$90K Hold
12,445
0.01% 63
2022
Q2
$106K Hold
12,445
0.01% 63
2022
Q1
$112K Buy
12,445
+2,000
+19% +$17.3K 0.01% 64
2021
Q4
$145K Hold
10,445
0.01% 61
2021
Q3
$111K Hold
10,445
0.01% 64
2021
Q2
$94K Hold
10,445
0.01% 66
2021
Q1
$111K Hold
10,445
0.01% 63
2020
Q4
$132K Hold
10,445
0.01% 66
2020
Q3
$92K Sell
10,445
-40,000
-79% -$366K 0.01% 57
2020
Q2
$490K Sell
50,445
-117,143
-70% -$507K 0.07% 51
2020
Q1
$483K Sell
167,588
-17,699
-10% -$55.1K 0.07% 51
2019
Q4
$712K Sell
185,287
-300
-0.2% -$935 0.07% 59
2019
Q3
$735K Buy
185,587
+64,224
+53% +$276K 0.08% 68
2019
Q2
$511K Sell
121,363
-1,609
-1% -$9.29K 0.06% 72
2019
Q1
$844K Hold
122,972
0.09% 62
2018
Q4
$453K Buy
+122,972
New +$607K 0.05% 73

Hikari Power's ALPN Position: Q2 2024 in Review

Hikari Power sold out of Alpine Immune Sciences Inc (ALPN) in Q2 2024, closing a stake of 12,445 shares — an estimated $493K sold.

Hikari Power first reported a position in ALPN in Q4 2018 and held it in 22 quarters. The position peaked at $844K in Q1 2019. 0 funds tracked by Wall St. Rank hold ALPN as of Q2 2024.

  • Hikari Power reported no remaining Alpine Immune Sciences Inc position as of Q2 2024 after selling out during the quarter.
  • Hikari Power sold 12,445 Alpine Immune Sciences Inc shares in Q2 2024, an estimated $493K.
  • Hikari Power first reported a position in Alpine Immune Sciences Inc in Q4 2018 and held it in 22 quarters.
  • Hikari Power's Alpine Immune Sciences Inc position peaked at $844K in Q1 2019.
  • 0 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q2 2024.

Based on Hikari Power's 13F filing for Q2 2024, filed 23 Jul 2024.